OnKure Therapeutics Inc.
Organization details
- Legal name
- OnKure Therapeutics Inc.
- Former names
- Reneo Pharmaceuticals, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Boulder
- Headquarters state / province
- Colorado
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- OKUR
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001637715
- EIN
- 47-2309515
Board of directors
-
Andrew John Phillips · DirectorSince 2024
-
Bali Muralidhar · DirectorSince 2023
- Since 2023
-
Eric M. Dube · DirectorSince 2023
-
Isaac Manke · DirectorSince 2024
-
Liam Ratcliffe · DirectorSince 2026
-
Michael G. Grey · Director · Executive ChairmanSince 2023
-
Niall O'Donnell · DirectorSince 2023
-
Nicholas A. Saccomano · Director · President and CEOSince 2024
-
Paul W. Hoelscher · DirectorSince 2023
-
R. Michael Carruthers · DirectorSince 2024
-
Roshawn A. Blunt · DirectorSince 2023
-
Stacey Denenberg Seltzer · DirectorSince 2023
-
Valerie Malyvanh Jansen · DirectorSince 2024
Chief executives
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.3%
-
99.3%
-
99.7%
Board connections
9 of this board's directors also sit on 16 other boards. 15 are in the same sector.
-
Spruce Biosciences Inc. Same sectorvia Bali Muralidhar, Michael G. Grey and Niall O'Donnell
-
Addex Therapeutics Ltd Same sectorvia Isaac Manke
-
Climb Bio Inc. Same sectorvia Liam Ratcliffe
-
Disc Medicine Inc. Same sectorvia Liam Ratcliffe
-
Enliven Therapeutics Inc. Same sectorvia Andrew John Phillips
-
MBX Biosciences Inc. Same sectorvia Edward T. Mathers
-
Mirum Pharmaceuticals Inc. Same sectorvia Michael G. Grey
-
MoonLake Immunotherapeutics Same sectorvia Andrew John Phillips
-
Q32 Bio Inc. Same sectorvia Isaac Manke
- via Isaac Manke
-
Rhythm Pharmaceuticals Inc. Same sectorvia Edward T. Mathers
-
Sagimet Biosciences Inc. Same sectorvia Paul W. Hoelscher
-
Senti Biosciences Holdings Inc. Same sectorvia Edward T. Mathers
-
Travere Therapeutics Inc. Same sectorvia Eric M. Dube
-
Trevi Therapeutics Inc. Same sectorvia Edward T. Mathers
-
Upstream Bio Inc. Same sectorvia Liam Ratcliffe
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $5,632
- 8 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 21, 2026 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −302 | $2.97 | $897 |
| Sep 21, 2026 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −87 | $2.97 | $258 |
| Jun 22, 2026 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −86 | $4.40 | $378 |
| Jun 22, 2026 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −303 | $4.40 | $1,333 |
| Mar 23, 2026 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −86 | $4.16 | $358 |
| Mar 23, 2026 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −301 | $4.16 | $1,252 |
| Dec 31, 2025 | Edward T. Mathers Director | Grant or award | +3,911 | — | — |
| Dec 31, 2025 | Isaac Manke Director | Grant or award | +5,258 | — | — |
| Dec 22, 2025 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −87 | $2.97 | $258 |
| Dec 22, 2025 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −302 | $2.97 | $897 |
| Sep 30, 2025 | Edward T. Mathers Director | Grant or award | +4,125 | — | — |
| Sep 30, 2025 | Isaac Manke Director | Grant or award | +5,545 | — | — |
| Sep 22, 2025 | Nicholas A. Saccomano Director, Officer (President and CEO) | Open-market sale | −88 | $2.62 | $231 |
| Sep 22, 2025 | Leverone Jason A. Officer (Chief Financial Officer) | Open-market sale | −303 | $2.62 | $794 |
| Jun 30, 2025 | Edward T. Mathers Director | Grant or award | +4,694 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about OnKure Therapeutics Inc.
Who is the CEO of OnKure Therapeutics Inc.?
Nicholas A. Saccomano has been OnKure Therapeutics Inc.'s President and CEO since October 2024.
How many directors are on OnKure Therapeutics Inc.'s board?
OnKure Therapeutics Inc.'s board has 14 directors: Andrew John Phillips, Bali Muralidhar, Edward T. Mathers, Eric M. Dube, Isaac Manke, Liam Ratcliffe, Michael G. Grey, Niall O'Donnell, Nicholas A. Saccomano, Paul W. Hoelscher and 4 others.
Are OnKure Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, OnKure Therapeutics Inc. insiders made no open-market purchases and sold $5,632 of shares in 8 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="onkure-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.